Literature DB >> 17869015

Temporal change in brain natriuretic Peptide after radiotherapy for thoracic esophageal cancer.

Keiichi Jingu1, Kenji Nemoto, Tomohiro Kaneta, Minako Oikawa, Yoshihiro Ogawa, Hisanori Ariga, Ken Takeda, Toru Sakayauchi, Keisuke Fujimoto, Kakutaro Narazaki, Yoshihiro Takai, Eiko Nakata, Hiroshi Fukuda, Shoki Takahashi, Shogo Yamada.   

Abstract

PURPOSE: To investigate the relationships of plasma levels of brain natriuretic peptide (BNP) with abnormal (18)F-fluorodeoxyglucose (FDG) accumulation in the myocardium corresponding to irradiated fields and temporal changes in BNP, which is used as an index of heart remodeling, after radiotherapy for the mediastinum.
MATERIALS AND METHODS: Brain natriuretic peptide concentrations were measured before and after radiotherapy for thoracic esophageal cancer, and the change in BNP concentration after radiotherapy was investigated. Moreover, FDG accumulation in the myocardium was investigated in patients who had undergone FDG positron emission tomography less than 14 days before or after measurement of BNP concentration, and the Mann-Whitney U test was used to detect significant difference between BNP concentrations in patients with and without abnormal FDG accumulation corresponding to the irradiated field.
RESULTS: There was significant difference between the levels of BNP in patients without abnormal FDG accumulation in the irradiated myocardium and in patients with abnormal FDG accumulation (p < 0.001). The levels of BNP in the 9-24 months after radiotherapy group and in the >24 months after radiotherapy group were significantly higher than the levels in the before radiotherapy group, immediately after radiotherapy group, 1-2 months after radiotherapy group, and control group.
CONCLUSIONS: The level of BNP was significantly increased more than 9 months after the start of radiotherapy and was significantly higher in patients who had high FDG accumulation corresponding to the irradiated field. The results of this study indicate that BNP concentration might be an early indicator of radiation-induced myocardial damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869015     DOI: 10.1016/j.ijrobp.2007.05.054

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Dose-Dependent Radiation-Induced Myocardial Damage in Esophageal Cancer Treated With Chemoradiotherapy: A Prospective Cardiac Magnetic Resonance Imaging Study.

Authors:  Rei Umezawa; Noriyuki Kadoya; Hideki Ota; Yujiro Nakajima; Masahide Saito; Hidenobu Takagi; Kentaro Takanami; Noriyoshi Takahashi; Yojiro Ishikawa; Takaya Yamamoto; Haruo Matsushita; Ken Takeda; Kei Takase; Keiichi Jingu
Journal:  Adv Radiat Oncol       Date:  2020-08-05

2.  Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.

Authors:  Mikael Lund; Gabriella Alexandersson von Döbeln; Magnus Nilsson; Reidar Winter; Lars Lundell; Jon A Tsai; Sigridur Kalman
Journal:  Radiat Oncol       Date:  2015-01-13       Impact factor: 3.481

3.  Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study.

Authors:  Rei Umezawa; Kentaro Takanami; Noriyuki Kadoya; Yujiro Nakajima; Masahide Saito; Hideki Ota; Haruo Matsushita; Toshiyuki Sugawara; Masaki Kubozono; Takaya Yamamoto; Yojiro Ishikawa; Ken Takeda; Yasuyuki Taki; Kei Takase; Keiichi Jingu
Journal:  Radiat Oncol       Date:  2015-04-21       Impact factor: 3.481

4.  Evaluation of radiation-induced myocardial damage using iodine-123 β-methyl-iodophenyl pentadecanoic acid scintigraphy.

Authors:  Rei Umezawa; Kei Takase; Keiichi Jingu; Kentaro Takanami; Hideki Ota; Tomohiro Kaneta; Ken Takeda; Haruo Matsushita; Hisanori Ariga; Shoki Takahashi; Shogo Yamada
Journal:  J Radiat Res       Date:  2013-02-14       Impact factor: 2.724

Review 5.  Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients.

Authors:  Sibo Tian; Kim M Hirshfield; Salma K Jabbour; Deborah Toppmeyer; Bruce G Haffty; Atif J Khan; Sharad Goyal
Journal:  Front Oncol       Date:  2014-10-09       Impact factor: 6.244

Review 6.  Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.

Authors:  Michelle W Bloom; Carine E Hamo; Daniela Cardinale; Bonnie Ky; Anju Nohria; Lea Baer; Hal Skopicki; Daniel J Lenihan; Mihai Gheorghiade; Alexander R Lyon; Javed Butler
Journal:  Circ Heart Fail       Date:  2016-01       Impact factor: 8.790

Review 7.  Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies.

Authors:  Michael A Biersmith; Matthew S Tong; Avirup Guha; Orlando P Simonetti; Daniel Addison
Journal:  J Am Heart Assoc       Date:  2020-01-21       Impact factor: 5.501

8.  Cardiac serum marker alterations after intraoperative radiotherapy with low-energy x-rays in early breast cancer as an indicator of possible cardiac toxicity.

Authors:  Stefan Stefanovic; Sebastian Berlit; Elena Sperk; Frederik Wenz; Christel Weiß; Frederik Trinkmann; Marc Sütterlin; Benjamin Tuschy
Journal:  Strahlenther Onkol       Date:  2020-08-19       Impact factor: 3.621

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.